You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

340 Results
This is FR page
Les informations suivantes répondent à de nombreuses questions fréquemment posées par les médecins de première ligne au sujet de l’inscription et de...
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Oct 2024
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
Apr 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
May 2025
Document

Pages